Cytori Therapeutics Closes Previously Announced $10 Million Offering

SAN DIEGO--()--Cytori Therapeutics, Inc. (NASDAQ: CYTX) has closed and received the net proceeds from the subscription agreements with certain institutional investors that the Company entered into on May 30, 2014 to raise $10 million, before placement agent fees and offering expenses.

WBB Securities, LLC acted as placement agent for the offering.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and rescue tissue at risk of dying. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® System product family. www.cytori.com

Contacts

Cytori Therapeutics, Inc.
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com

Release Summary

Cytori has closed and received the net proceeds from the subscription agreements with certain institutional investors to raise $10 million, before placement agent fees and offering expenses.

Sharing

Contacts

Cytori Therapeutics, Inc.
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com